vs
Bone Biologics Corp（BBLG）与Envoy Medical, Inc.（COCH）财务数据对比。点击上方公司名可切换其他公司
Envoy Medical, Inc.的季度营收约是Bone Biologics Corp的294.1倍（$75.0K vs $255）。Envoy Medical, Inc.净利率更高（-8781.3% vs -339596.1%，领先330814.7%）。Envoy Medical, Inc.同比增速更快（78.6% vs -54.1%）
Bone Biologics Corp是一家临床阶段生物技术企业，专注研发用于脊柱融合等骨科手术的骨再生修复生物制剂，主要面向美国医疗市场，核心业务覆盖骨科护理及再生医学领域。
Envoy Medical是一家专注于植入式听力解决方案研发和商业化的医疗科技企业，核心产品为全植入式中耳听力设备，主要服务于使用常规外置助听器效果不佳的感音神经性听力损失患者，市场覆盖北美、欧洲等地区。
BBLG vs COCH — 直观对比
营收规模更大
COCH
是对方的294.1倍
$255
营收增速更快
COCH
高出132.7%
-54.1%
净利率更高
COCH
高出330814.7%
-339596.1%
损益表 — Q1 2024 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $255 | $75.0K |
| 净利润 | $-866.0K | $-6.6M |
| 毛利率 | — | -181.3% |
| 营业利润率 | -354327.8% | -8513.3% |
| 净利率 | -339596.1% | -8781.3% |
| 营收同比 | -54.1% | 78.6% |
| 净利润同比 | 76.7% | -42.6% |
| 每股收益（稀释后） | $-1.31 | $-0.27 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BBLGCOCH
| Q4 25 | — | $75.0K | ||
| Q3 25 | — | $42.0K | ||
| Q2 25 | — | $78.0K | ||
| Q1 25 | — | $46.0K | ||
| Q4 24 | — | $42.0K | ||
| Q3 24 | — | $56.0K | ||
| Q2 24 | — | $68.0K | ||
| Q1 24 | $255 | $59.0K |
净利润BBLGCOCH
| Q4 25 | — | $-6.6M | ||
| Q3 25 | — | $-6.5M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | — | $-5.0M | ||
| Q4 24 | — | $-4.6M | ||
| Q3 24 | — | $-6.0M | ||
| Q2 24 | — | $-3.9M | ||
| Q1 24 | $-866.0K | $-6.3M |
毛利率BBLGCOCH
| Q4 25 | — | -181.3% | ||
| Q3 25 | — | -383.3% | ||
| Q2 25 | — | -200.0% | ||
| Q1 25 | — | -391.3% | ||
| Q4 24 | — | -273.8% | ||
| Q3 24 | — | -233.9% | ||
| Q2 24 | — | -260.3% | ||
| Q1 24 | — | -159.3% |
营业利润率BBLGCOCH
| Q4 25 | — | -8513.3% | ||
| Q3 25 | — | -13590.5% | ||
| Q2 25 | — | -6500.0% | ||
| Q1 25 | — | -11102.2% | ||
| Q4 24 | — | -10828.6% | ||
| Q3 24 | — | -8878.6% | ||
| Q2 24 | — | -7135.3% | ||
| Q1 24 | -354327.8% | -8278.0% |
净利率BBLGCOCH
| Q4 25 | — | -8781.3% | ||
| Q3 25 | — | -15433.3% | ||
| Q2 25 | — | -7294.9% | ||
| Q1 25 | — | -10865.2% | ||
| Q4 24 | — | -10995.2% | ||
| Q3 24 | — | -10642.9% | ||
| Q2 24 | — | -5804.4% | ||
| Q1 24 | -339596.1% | -10627.1% |
每股收益（稀释后）BBLGCOCH
| Q4 25 | — | $-0.27 | ||
| Q3 25 | — | $-0.35 | ||
| Q2 25 | — | $-0.32 | ||
| Q1 25 | — | $-0.29 | ||
| Q4 24 | — | $-0.40 | ||
| Q3 24 | — | $-0.39 | ||
| Q2 24 | — | $-0.29 | ||
| Q1 24 | $-1.31 | $-0.41 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $3.7M | $-12.2M |
| 总资产 | $3.8M | $8.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
股东权益BBLGCOCH
| Q4 25 | — | $-12.2M | ||
| Q3 25 | — | $-7.7M | ||
| Q2 25 | — | $-29.9M | ||
| Q1 25 | — | $-24.2M | ||
| Q4 24 | — | $-18.8M | ||
| Q3 24 | — | $-18.5M | ||
| Q2 24 | — | $-12.4M | ||
| Q1 24 | $3.7M | $-7.4M |
总资产BBLGCOCH
| Q4 25 | — | $8.6M | ||
| Q3 25 | — | $8.2M | ||
| Q2 25 | — | $9.9M | ||
| Q1 25 | — | $10.4M | ||
| Q4 24 | — | $11.5M | ||
| Q3 24 | — | $9.4M | ||
| Q2 24 | — | $6.7M | ||
| Q1 24 | $3.8M | $8.5M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.3M | $-5.7M |
| 自由现金流经营现金流 - 资本支出 | — | $-5.9M |
| 自由现金流率自由现金流/营收 | — | -7809.3% |
| 资本支出强度资本支出/营收 | — | 229.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BBLGCOCH
| Q4 25 | — | $-5.7M | ||
| Q3 25 | — | $-4.3M | ||
| Q2 25 | — | $-4.5M | ||
| Q1 25 | — | $-3.7M | ||
| Q4 24 | — | $-5.1M | ||
| Q3 24 | — | $-2.6M | ||
| Q2 24 | — | $-4.6M | ||
| Q1 24 | $-1.3M | $-5.6M |
自由现金流BBLGCOCH
| Q4 25 | — | $-5.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-4.5M | ||
| Q1 25 | — | $-3.7M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-3.8M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-5.7M |
自由现金流率BBLGCOCH
| Q4 25 | — | -7809.3% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -5719.2% | ||
| Q1 25 | — | -8110.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -6750.0% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -9657.6% |
资本支出强度BBLGCOCH
| Q4 25 | — | 229.3% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 1.3% | ||
| Q1 25 | — | 13.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2066.1% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 184.7% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
